drugset / Trial / NCT01506596
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effectiveness and safety of single agent pazopanib in subjects with unresectable or metastatic liposarcoma.
Timeline
- Start
- 2012-03
- Primary completion
- 2014-10
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | 800 mg | Oral |